Pureos Bioventures will be investing in private, innovative drug development companies primarily located in Switzerland, the UK, the European Union, Canada and the United States. The Fund will focus on companies developing the next generation of biologics which include therapeutic antibodies, engineered protein and enzyme drugs, cellular therapies, engineered viruses and bacteria, and DNA- and RNA-modifying technologies, using advanced molecular biology and biochemistry. The Fund will consider companies with programs in pre-clinical and early clinical stages and aims to stay invested during phases of highest value generation. The Fund will focus on indications with high medical need, as it aims to invest in the development of novel medicines to address diseases, which cannot yet be cured or sufficiently managed. BB Pureos Bioventures aims to take significant stakes (10–20%) and looks to be actively involved at the board level of its portfolio companies.